AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable
AgeX Therapeutics (NYSE:AGE) Frequently Asked Questions
What is AgeX Therapeutics' stock symbol?
AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."
When is AgeX Therapeutics' next earnings date?
Has AgeX Therapeutics been receiving favorable news coverage?
Headlines about AGE stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. AgeX Therapeutics earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for AgeX Therapeutics.
What other stocks do shareholders of AgeX Therapeutics own?
Who are AgeX Therapeutics' key executives?
AgeX Therapeutics' management team includes the folowing people:
- Mr. Alfred D. Kingsley, Exec. Chairman (Age 75)
- Dr. Michael D. West, Pres, CEO & Director (Age 65)
- Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
- Mr. Nafees Naseer Malik, Chief Operating Officer
- Dr. Aubrey D. N. J. de Grey BA, MA,Ph.D., Vice-Pres of New Technology Discovery
Who are AgeX Therapeutics' major shareholders?
AgeX Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (0.70%), Defender Capital LLC. (0.37%), Panagora Asset Management Inc. (0.21%), UBS Group AG (0.09%) and Barclays PLC (0.06%). View Institutional Ownership Trends for AgeX Therapeutics.
Which major investors are selling AgeX Therapeutics stock?
Which major investors are buying AgeX Therapeutics stock?
How do I buy shares of AgeX Therapeutics?
Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AgeX Therapeutics' stock price today?
One share of AGE stock can currently be purchased for approximately $1.40.
MarketBeat Community Rating for AgeX Therapeutics (NYSE AGE)
MarketBeat's community ratings are surveys of what our community members think about AgeX Therapeutics and other stocks. Vote "Outperform" if you believe AGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
